Liminal BioSciences Inc. LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc. > LMNL Mar 25 '21 Transcript Seeking Alpha

<< Previous

Bullboard Posts

Next >>

Comment by stockbuphoonon May 08, 2021 11:17am

86 Views

Post# 33159694

RE: LMNL Mar 25 '21 Transcript Seeking Alpha

Realstocky/Newcamo (same guy behind both boardnames), You are saying they reviewed Ryplazim and it was "no problem" but it took 3 years and over $360M of spending to resolve the 4 "easy" checkpoints. There is no hope of a distribution deal as the mgmt clearly have said so that is a lie. You still cannot spell Ryplazim after years of pumping it? Something very strange there. The FDA extended their PDUFA date 3 months as there was significant new information on the CMC to review. After 2.5 years of work on these "early checkpoints", they introduced new information. How stupid is that? It's almost like they are trying to have it fail so they can close down the company and take it private secretly selling the small molecule business to Boehringher? That would make perfect sense with the disgusting moves already taken by Thomson. $50B in bank and he still fleeces a ton of small investors. And you trust them?

realstocky wrote:

he's being on record so he's covering all bases, we all know if we dont get the FDA green light, riplazym is done. But odds are we'll be fine, read below:

Next:1- FDA riplazym approval 2- riplazym distribution deal 3- priority voucher potentially worth 120million$ or more... market cap is also around 120M$....

:::

FDA already reviewed riplazym and it was no problem, only asked for aditional check points... i think this time we'll get it! LMNL also hired a quality assurance specialist moira daniels, i bet to please the FDA.

conference call info from weeks ago
" I think it's without giving anything away on what we're doing with negotiations and discussions that would be commercially sensitive. The reality is that we are looking at all opportunities here, whether we do this before or after Ryplazim approval. "<<<< =================

incoming........$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

=================================================================

confirmed as well on latest NR

PDUFA target action date of June 5, 2021 for Ryplazim

"2021 has the potential to be a transformative one for Liminal BioSciences as we progress our evaluation of strategic alternatives for our plasma-derived therapeutics business, while continuing to work towards the PDUFA target action date of June 5, 2021 for Ryplazim ® (plasminogen)," stated Patrick Sartore , President of Liminal BioSciences.